We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.47B
AUM Growth
+$23.6M
Cap. Flow
+$142M
Cap. Flow %
5.74%
Top 10 Hldgs %
53.52%
Holding
129
New
25
Increased
23
Reduced
34
Closed
26

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$125M
2
Z icon
Zillow
Z
+$35.8M
3
UBER icon
Uber
UBER
+$21.2M
4
CYCN
Cyclerion Therapeutics
CYCN
+$19.3M
5
HOOK
HOOKIPA Pharma
HOOK
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$48.8M
2
IFRX icon
InflaRx
IFRX
+$31.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$11M
4
WVE icon
Wave Life Sciences
WVE
+$9.71M
5
VICI icon
VICI Properties
VICI
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 65.51%
2 Consumer Discretionary 15.74%
3 Miscellaneous 12.06%
4 Technology 4.81%
5 Communication Services 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
26
Atara Biotherapeutics
ATRA
$93M
$23.1M 0.94%
46,000
– –
MLCO icon
27
CALL
Melco Resorts & Entertainment
MLCO
$1.79B
$21.7M 0.88%
1,000,000
+250,000
+33% +$5.67M
INCY icon
28
CALL
Incyte
INCY
$24.7B
$21.2M 0.86%
+250,000
New +$20.1M
EPZM
29
DELISTED
Epizyme, Inc
EPZM
$20.7M 0.84%
1,650,000
-100,000
-6% -$1.29M
ASND icon
30
Ascendis Pharma A/S
ASND
$15.5B
$17.3M 0.7%
150,000
+25,000
+20% +$2.99M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$4.18B
$17.2M 0.69%
700,000
+200,000
+40% +$3.01M
NBIX icon
32
CALL
Neurocrine Biosciences
NBIX
$15.3B
$16.9M 0.68%
200,000
– –
NVDA icon
33
CALL
NVIDIA
NVDA
$5.12T
$16.4M 0.66%
+4,000,000
New +$16.6M
AAL icon
34
CALL
American Airlines Group
AAL
$8.47B
$16.3M 0.66%
500,000
– –
DRNA
35
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$15.8M 0.64%
1,000,000
+20,725
+2% +$282K
CYCN
36
DELISTED
Cyclerion Therapeutics
CYCN
$15.6M 0.63%
+68,079
New +$19.3M
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.4M 0.62%
150,000
-25,000
-14% -$1.95M
ALBO
38
DELISTED
Albireo Pharma Inc
ALBO
$14.5M 0.59%
450,000
-50,000
-10% -$1.67M
TCDA
39
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.2M 0.57%
360,000
+135,000
+60% +$4.75M
BOLD
40
DELISTED
Audentes Therapeutics, Inc
BOLD
$13.3M 0.54%
350,000
-50,000
-13% -$1.92M
BLUE
41
DELISTED
bluebird bio
BLUE
$12.7M 0.51%
7,720
– –
HTHT icon
42
Huazhu Hotels Group
HTHT
$13.3B
$12.7M 0.51%
350,000
+200,000
+133% +$7.48M
NIO icon
43
NIO
NIO
$9B
$12.4M 0.5%
4,850,000
+250,000
+5% +$1M
KRYS icon
44
Krystal Biotech
KRYS
$10B
$12.1M 0.49%
300,000
– –
PRQR icon
45
ProQR Therapeutics
PRQR
$258M
$11.8M 0.48%
1,300,000
-100,000
-7% -$1.18M
XNCR icon
46
Xencor
XNCR
$1.76B
$11.3M 0.46%
275,000
-225,000
-45% -$7.39M
CHNG
47
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$10.9M 0.44%
+750,000
New +$11.1M
ALNY icon
48
CALL
Alnylam Pharmaceuticals
ALNY
$32.4B
$10.9M 0.44%
+150,000
New +$11.5M
KLDO
49
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$10.4M 0.42%
900,500
-46,919
-5% -$683K
AXDX
50
DELISTED
Accelerate Diagnostics
AXDX
$10.3M 0.42%
45,000
-5,000
-10% -$978K
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2019 Portfolio in Review

As of Q2 2019, Artal Group held 129 positions worth $2.47B, up 0.96% from $2.45B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Artal Group deployed $142M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was Avantor: 7,000,000 shares worth $134M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 65% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Moderna, an estimated $8.59M trimmed.

  • Artal Group's largest Q2 2019 buy was Avantor: 7,000,000 shares worth $134M.
  • Artal Group added most to Zillow in Q2 2019, an estimated $35.8M increase.
  • Artal Group's biggest Q2 2019 reduction was Moderna, cutting an estimated $8.59M.
  • Artal Group fully exited Array Biopharma Inc in Q2 2019, selling an estimated $48.8M.
  • Artal Group's ten largest holdings make up 54% of its $2.47B portfolio in Q2 2019.
  • Artal Group opened 25 new positions and closed 26 in Q2 2019.
  • Artal Group's portfolio value rose 0.96% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.